STERISHEALTHCAREPVTLTDADA8 Medicines
Jaipur 08048129013 boost@sterispharma.com
918955945010
Chat with us  

Chat with us on WhatsApp

×
Preview

This is your website preview.

Currently it only shows your basic business info. Start adding relevant business details such as description, images and products or services to gain your customers attention by using Boost 360 android app / iOS App / web portal.

STERISHEALTHCAREPVTLTDADA8 65b0b7e3912bef38d51b547d Medicines https://www.sterispharma.com
Home
medicines
Quote
Menu

Steris Healthcare Pvt Ltd, We are delighted to introduce ourselves as STERIS HEALTHCARE PVT LTD is a specialty pharmaceutical company formed in the February month of year 2015 by a group of extensively proficient pharmaceutical pr ...

Steris Healthcare Pvt Ltd, We are delighted to introduce ourselves as STERIS HEALTHCARE PVT LTD is a specialty pharmaceutical company formed in the February month of year 2015 by a group of e... read more

VIEW medicines
CONTACT US

Our Medicines

SEIZMET 500 Metformin HydrochlorideIntroduction:Diabetes mellitus, a chronic metabolic disorder, poses a significant global health burden, necessitating effective management strategies to mitigate its complications. Metformin hydrochloride has long been established as a first-line therapy for type 2 diabetes mellitus (T2DM) due to its efficacy, safety profile, and cardiovascular benefits. SEIZMET 500, featuring Metformin Hydrochloride at a dosage of 500mg, represents a cornerstone in the management of T2DM. This article explores the features, efficacy, safety profile, and clinical implications of SEIZMET 500 in diabetes care.Understanding Metformin Hydrochloride:Metformin hydrochloride belongs to the class of biguanide antidiabetic medications. Its primary mechanism of action involves reducing hepatic glucose production, enhancing peripheral glucose uptake, and improving insulin sensitivity. Additionally, Metformin exerts beneficial effects on lipid metabolism and may contribute to weight loss in patients with T2DM.Key Features of SEIZMET 500:SEIZMET 500 is a pharmaceutical formulation containing Metformin Hydrochloride at a standardized dosage of 500mg per tablet. This dosage strength offers clinicians the flexibility to titrate doses according to individual patient needs, ensuring optimal glycemic control while minimizing the risk of adverse effects. The formulation of SEIZMET 500 ensures consistency and reliability in dosing, facilitating effective diabetes management.Efficacy in Glycemic Control:Clinical studies have demonstrated the efficacy of Metformin Hydrochloride, including SEIZMET 500, in improving glycemic control in patients with T2DM. Metformin has been shown to reduce hemoglobin A1c (HbA1c) levels, fasting plasma glucose, and postprandial glucose excursions, leading to improvements in overall glucose regulation. Additionally, Metformin may offer cardiovascular benefits and is associated with a reduced risk of macrovascular complications in patients with T2DM.For further information: EMAIL: info@sterispharma.com / contact@sterispharma.com CALL/WHATSAPP:: 7877551268, 8209542042, 8955945010, 6377716668 https://www.sterisonline.com/product/seizmet-500-134073
Buy Now
Add to cart
View Details
SEIZMET 500

INR 20 INR 28
You Save: INR 28.57%

View Details
RAPIGLINIDE VOG 0.5 Repaglinide (0.5mg), Voglibose (0.3mg)Introduction:In the endeavor to manage diabetes effectively, the combination of medications with complementary mechanisms of action has gained prominence. Repaglinide and voglibose represent two such agents that target different aspects of glucose regulation. RAPIGLINIDE VOG 0.5 combines repaglinide (0.5mg) and voglibose (0.3mg) to provide comprehensive glycemic control. This article explores the features, efficacy, safety profile, and clinical implications of RAPIGLINIDE VOG 0.5 in diabetes management.Understanding Repaglinide and Voglibose:Repaglinide is a rapid-acting insulin secretagogue that stimulates insulin release from pancreatic beta cells, particularly after meals, thereby lowering blood glucose levels. Voglibose, on the other hand, is an alpha-glucosidase inhibitor that delays carbohydrate digestion and absorption in the intestine, leading to reduced postprandial glucose spikes. By targeting different pathways, repaglinide and voglibose complement each other to achieve optimal glycemic control.Key Features of RAPIGLINIDE VOG 0.5:RAPIGLINIDE VOG 0.5 is a fixed-dose combination tablet containing repaglinide (0.5mg) and voglibose (0.3mg). This standardized formulation offers the convenience of combining two effective antidiabetic agents in a single tablet, simplifying medication regimens and enhancing patient adherence. The combination of repaglinide and voglibose provides a synergistic effect, allowing for better control of both fasting and postprandial hyperglycemia.Efficacy in Glycemic Control:Clinical studies have demonstrated the efficacy of RAPIGLINIDE VOG 0.5 in improving glycemic control in patients with type 2 diabetes mellitus (T2DM). The combination of repaglinide and voglibose has been shown to reduce hemoglobin A1c (HbA1c) levels, fasting plasma glucose, and postprandial glucose excursions, leading to improvements in overall glucose regulation. Additionally, the rapid onset of action of repaglinide and the sustained effect of voglibose contribute to better glycemic control throughout the day.For further information: EMAIL: info@sterispharma.com / contact@sterispharma.com CALL/WHATSAPP:: 7877551268, 8209542042, 8955945010, 6377716668 https://www.sterisonline.com/product/rapiglinide-vog-0-5-134238
Buy Now
Add to cart
View Details
RAPIGLINIDE VOG 0.5

INR 102 INR 145
You Save: INR 29.66%

View Details
RAPIGLINIDE VOG 1.0 Repaglinide (1mg), Voglibose (0.3mg)Introduction:Effective management of diabetes mellitus requires a multifaceted approach that targets various aspects of glucose regulation. Repaglinide and voglibose are two medications that offer unique mechanisms of action in controlling blood sugar levels. RAPIGLINIDE VOG 1.0 combines repaglinide (1mg) and voglibose (0.3mg) to provide comprehensive glycemic control. This article explores the features, efficacy, safety profile, and clinical implications of RAPIGLINIDE VOG 1.0 in diabetes management.Understanding Repaglinide and Voglibose:Repaglinide is a rapid-acting insulin secretagogue that stimulates insulin release from pancreatic beta cells, particularly after meals, thereby lowering blood glucose levels. Voglibose, on the other hand, is an alpha-glucosidase inhibitor that delays carbohydrate digestion and absorption in the intestine, leading to reduced postprandial glucose spikes. By targeting different pathways, repaglinide and voglibose complement each other to achieve optimal glycemic control.Key Features of RAPIGLINIDE VOG 1.0:RAPIGLINIDE VOG 1.0 is a fixed-dose combination tablet containing repaglinide (1mg) and voglibose (0.3mg). This standardized formulation offers the convenience of combining two effective antidiabetic agents in a single tablet, simplifying medication regimens and enhancing patient adherence. The combination of repaglinide and voglibose provides a synergistic effect, allowing for better control of both fasting and postprandial hyperglycemia.Efficacy in Glycemic Control:Clinical studies have demonstrated the efficacy of RAPIGLINIDE VOG 1.0 in improving glycemic control in patients with type 2 diabetes mellitus (T2DM). The combination of repaglinide and voglibose has been shown to reduce hemoglobin A1c (HbA1c) levels, fasting plasma glucose, and postprandial glucose excursions, leading to improvements in overall glucose regulation. Additionally, the rapid onset of action of repaglinide and the sustained effect of voglibose contribute to better glycemic control throughout the day.Safety Profile:RAPIGLINIDE VOG 1.0 exhibits a favorable safety profile, with adverse effects typically mild to moderate in severity. Common side effects may include gastrointestinal symptoms such as abdominal discomfort, diarrhea, or flatulence, which are often transient and diminish with continued use. Both repaglinide and voglibose are generally well-tolerated medications, with a low risk of hypoglycemia when used alone or in combination. For further information: EMAIL: info@sterispharma.com / contact@sterispharma.com CALL/WHATSAPP:: 7877551268, 8209542042, 8955945010, 6377716668 https://www.sterisonline.com/product/rapiglinide-vog-1-0-134237
Buy Now
Add to cart
View Details
RAPIGLINIDE VOG 1.0

INR 133 INR 189
You Save: INR 29.63%

View Details
View All Medicines
about Steris Pharma

about our organization

Steris Healthcare Pvt Ltd, We are delighted to introduce ourselves as STERIS HEALTHCARE PVT LTD is a specialty pharmaceutical company formed in the February month of year 2015 by a group of extensively proficient pharmaceutical pr...Read More

  • 926

    Medicines Available

lATEST NEWS

STERIMMUNE WOMEN ACTIV Multivitamin, Multimineral Protein Powder STERIMMUNE WOMEN ACTIV ,...

Read More
Read More

THIOCOTERIS PCM ACE Thiocolchicoside (4mg) ,Aceclofenac (100mg) & Paracetamol (352mg) THI...

Read More
Read More

DONEPAZE 5 Donepazil (5mg) DONEPAZE 5 is a medication containing Donepezil at a strength ...

Read More
Read More
VIEW ALL UPDATES

Request a Call Back

Any Questions About Us?


If you have any kind of query, please don't hesitate to contact us on our Email and you can also contact by calling 08048129013


Chat with us  

Customers

Opening Hours

    Subscribe Us

    Subscribe to our newsletter!
    Steris Pharma

    Social share